Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Su

Showing results (801-810 of 830) with videos related to

Pageof 83
Sort By:
Aging|October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open|March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell LymphomaXin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
Nature|June 3, 2021
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variantsZhiqiang Ku, Xuping Xie, Paul R Hinton, et al.
The American Journal of Psychiatry|March 19, 2025
Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and GuidelineVictor M Tang, Scott Aaronson, Mohamed Abdelghani, et al.
Cancer Reports (Hoboken, N.J.)|March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphomaJia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Pageof 83

Showing results (801-810 of 830) with videos related to

Sort By:
Pageof 83
Aging|October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open|March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell LymphomaXin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances|September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative GroupTao Wu, Yong Yang, Su-Yu Zhu, et al.
Nature|June 3, 2021
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variantsZhiqiang Ku, Xuping Xie, Paul R Hinton, et al.
The American Journal of Psychiatry|March 19, 2025
Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and GuidelineVictor M Tang, Scott Aaronson, Mohamed Abdelghani, et al.
Cancer Reports (Hoboken, N.J.)|March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphomaJia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Pageof 83